Xilio Therapeutics Inc (XLO): Next-Year EPS Estimate 31.09%
As of 2026-11-06, Xilio Therapeutics Inc (XLO) has a next-year EPS growth estimate of 31.09%. Featured in our EPS revision report on 2026-11-03.
On 2026-10-26, analyst consensus for XLO's next-year EPS growth shifted from 31.08% to 31.09% — a positive change of 0.01 percentage points. The revised estimate has been sustained across 11 subsequent trading sessions. Current-year growth is projected at 31.30%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 31.09%
- EPS growth this year
- 31.30%
- EPS next quarter (est)
- -$0.94
- Last price
- $8.50
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 31.09% | 31.30% | -$0.94 | $8.50 |
| 2026-11-05 | 31.09% | 31.30% | -$0.94 | $8.50 |
| 2026-11-04 | 31.09% | 31.30% | -$0.94 | $8.71 |
| 2026-11-03 | 31.09% | 31.30% | -$0.94 | $8.68 |
| 2026-11-02 | 31.09% | 31.30% | -$0.94 | $7.99 |
| 2026-10-31 | 31.09% | 31.30% | -$0.94 | $8.03 |
| 2026-10-30 | 31.09% | 31.30% | -$0.94 | $8.03 |
| 2026-10-29 | 31.09% | 31.30% | -$0.94 | $7.77 |
| 2026-10-28 | 31.09% | 31.30% | -$0.94 | $8.01 |
| 2026-10-27 | 31.09% | 31.30% | -$0.94 | $8.01 |
| 2026-10-26 | 31.09% | 31.30% | -$0.94 | $7.31 |
| 2026-10-23 | 31.08% | 31.26% | -$0.94 | $7.57 |
| 2026-10-22 | 31.08% | 31.26% | -$0.94 | $8.03 |
| 2026-10-21 | 31.08% | 31.26% | -$0.94 | $8.43 |
| 2026-05-12 | 115.06% | 42.96% | -$0.58 | $7.73 |
| 2026-05-11 | 115.06% | 42.96% | -$0.66 | $7.73 |
| 2026-05-10 | 115.06% | 42.96% | -$0.66 | $7.74 |
| 2026-05-07 | 115.06% | 42.96% | -$0.66 | $7.81 |
| 2026-05-06 | 115.06% | 42.96% | -$0.66 | $7.90 |
| 2026-05-05 | 115.06% | 42.96% | -$0.66 | $7.71 |
| 2026-05-04 | 115.06% | 42.96% | -$0.66 | $8.33 |
| 2026-05-03 | 115.06% | 42.96% | -$0.66 | $8.32 |
| 2026-04-30 | 115.06% | 42.96% | -$0.66 | $7.92 |
| 2026-04-29 | 115.06% | 42.96% | -$0.66 | $7.79 |
| 2026-04-28 | 115.06% | 42.96% | -$0.66 | $7.92 |
| 2026-04-27 | 115.06% | 42.96% | -$0.66 | $8.18 |
| 2026-04-26 | 115.06% | 42.96% | -$0.66 | $8.31 |
| 2026-04-24 | 115.06% | 42.96% | -$0.66 | $8.31 |
| 2026-04-23 | 115.06% | 42.96% | -$0.66 | $8.47 |
| 2026-04-22 | 115.06% | 42.96% | -$0.66 | $8.60 |
Reports Featuring XLO
Recent News
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Xilio Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-06, Xilio Therapeutics Inc (XLO) has a next-year EPS growth estimate of 31.09%, based on analyst consensus.
When was the latest EPS estimate revision for XLO?▾
The most recent revision occurred on 2026-10-26, when analysts adjusted the next-year EPS growth estimate from 31.08% to 31.09%.
What sector and industry does Xilio Therapeutics Inc belong to?▾
Xilio Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. XLO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Xilio Therapeutics Inc (XLO) appears here because it was detected by our daily top-EPS-revision-performer screen.